REGN REGENERON PHARMACEUTICALS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 872589 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY18.6%
TTM net income YoY5.2%
TTM EPS YoY8.4%
Revenue 3-yr CAGR8.9%
Net income 3-yr CAGR6.5%
Margins
Gross margin—
Operating margin28.8%
Net margin28.5%
FCF margin22.6%
EBITDA margin31.8%
Returns
ROE14.9%
ROA11.4%
ROIC (approx.)13.2%
Asset turnover0.40x
Leverage & solvency
Liabilities / assets24.6%
Debt / equity0.06x
Current ratio3.35x
Interest coverage104.16x
Cash quality & payout
Operating cash flow / net income1.01x
Accruals ratio-0.1%
Payout ratio8.0%
Capex / revenue6.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $14.34B | $14.20B |
| R&D expense | $5.85B | $5.13B |
| SG&A expense | $2.70B | $2.95B |
| Operating income | $3.58B | $3.99B |
| Interest expense | $43.80M | $55.20M |
| Pretax income | $5.23B | $4.78B |
| Income tax | $725.80M | $367.30M |
| Net income | $4.50B | $4.41B |
| EBITDA | $4.12B | $4.47B |
| EPS (basic) | 43.07 | 40.90 |
| EPS (diluted) | 41.48 | 38.34 |
| Weighted avg. shares (diluted) | 108.60M | 115.10M |
| Balance sheet | ||
| Cash & equivalents | $3.12B | $2.49B |
| Short-term investments | $5.49B | $6.52B |
| Receivables | $5.74B | $6.21B |
| Inventory | $3.20B | $3.09B |
| Current assets | $18.02B | $18.66B |
| PP&E, net | $5.12B | $4.60B |
| Intangibles | $1.26B | $1.15B |
| Total assets | $40.56B | $37.76B |
| Current liabilities | $4.37B | $3.94B |
| Long-term debt | $1.99B | $1.98B |
| Total debt | $1.99B | $1.98B |
| Total liabilities | $9.30B | $8.41B |
| Shareholders' equity | $31.26B | $29.35B |
| Net debt | -$1.13B | -$504.60M |
| Cash flow statement | ||
| Operating cash flow | $4.98B | $4.42B |
| Capital expenditure | $898.40M | $755.90M |
| Free cash flow | $4.08B | $3.66B |
| Investing cash flow | -$629.10M | -$2.47B |
| Financing cash flow | -$3.72B | -$2.20B |
| Depreciation & amortization | $543.70M | $482.90M |
| Stock-based compensation | $993.70M | $982.80M |
| Dividends paid | $370.30M | $0 |
| Share buybacks | $3.44B | $2.60B |
Free plan shows the latest 2 periods; Pro shows all 18 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.